Stacey Fahrner Joins Prime Therapeutics as Vice President, Government Affairs

Wednesday, February 17, 2010 Press Release
Email Print This Page Comment
Font : A-A+



ST. PAUL, Minn., Feb. 16 Prime Therapeutics (Prime) announced today that it has hired Stacey Fahrner as Vice President, Government Affairs. Fahrner will represent Prime's capabilities, business model and approach to pharmacy management to policymakers in Washington, DC and on the state level, and she will lead the company's response to a variety of legislative and policy issues. She will also represent Prime on key committees and associations. Fahrner will be based in Washington, DC.

"Stacey brings extensive experience in pharmacy and healthcare-related government affairs to the Prime team," said Matt Yordy, Senior Vice President for Business Development of Prime. "Stacey's leadership will help us continue to shape and build Prime's voice in the national health care arena. She also will help us leverage our expertise as a leader in pharmacy benefits issues at the state level."

Prior to joining Prime, Ms. Fahrner served as a Senior Policy Manager at the Blue Cross and Blue Shield Association in Washington, DC. Prior to that, she was a Senior Policy Manager at Abbott Laboratories in Chicago. She received her undergraduate degree from the University of Michigan, a master's degree in Public Health from Boston University and a Juris Doctor from Loyola University in Chicago.

Prime Therapeutics is a pharmacy benefit management company dedicated to providing innovative, clinically-based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to approximately 14.7 million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third- party administrators. Headquartered in St. Paul, Minnesota, Prime Therapeutics is collectively owned by 11 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at www.primetherapeutics.com.

© Prime Therapeutics LLC 12/09

SOURCE Prime Therapeutics


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook